PuSH - Publikationsserver des Helmholtz Zentrums München

Amadi, P.U.* ; Osuoha, J.O.* ; Ekweogu, C.N.* ; Jarad, S.J.* ; Efiong, E.E. ; Odika, P.C.* ; Ejiofor, C.* ; Aloy-Amadi, O.* ; Gill, G.S.* ; Adumekwe, C.W.* ; Gaowa, A.* ; Zhang, D.* ; de Courten, B.* ; Agomuo, E.N.*

Phenolic acids from Anisopus mannii modulates phosphofructokinase 1 to improve glycemic control in patients with type 2 diabetes: A double-blind, randomized, clinical trial.

Pharmacol. Res. 212:107602 (2025)
Verlagsversion Forschungsdaten DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Phenolic acid-rich fraction from Anisopus mannii (PhAM) contains abundance of ferulic acid, gallic acid, protocatechuic acid, and syringic acid. Among other glycolytic enzymes, in vitro, PhAM counteracted the binding of sodium orthovanadate to phosphofructokinase 1 (PFK-1), improving its activities. In a rat model of diet-induced diabetes, PhAM monotherapy reduced HbA1c by an average of 0.63% and fasting plasma glucose by 25mg/dl. This herb rescued β-cells from streptozotocin-mediated destruction, thereby improving glycemic control. Supported by the preclinical trial, eighty-five patients with type 2 diabetes (T2D) receiving first-line medications were enrolled in a double-blind, randomized, placebo-controlled trial with a 90% power level. Patients were randomized into a placebo group or either of the following two treatment groups: oral administration of 12mg or 20mg/kg body weight of PhAM once every 48h for 6 months. Both treatments were well tolerated. At the endpoint, more than 70% of patients achieved a 0.5 - 2.0 decrease in HbA1c levels and a >20mg/dl decrease in fasting blood glucose, meeting the pre-specified primary outcome. 66% of patients treated with 20mg PhAM achieved the < 7% HbA1c and HOMA-IR of > 1.0 goal. respectively. Our study shows that PhAM can supplement first-line medications to achieve target glycemic control within 6 months. Pan African Clinical Trial Registration number: PACTR202206531545729.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Anisopus Mannii ; Diabetes ; Hba1c ; Phosphofructokinase 1 ; Randomized Trial; Initial Combination Therapy; European Association; Glucose-metabolism; High-fat; Metformin; Mellitus; Insulin; Liver; Mice; Bisleuconothine
ISSN (print) / ISBN 1043-6618
e-ISSN 1096-1186
Zeitschrift Pharmacological Research
Quellenangaben Band: 212, Heft: , Seiten: , Artikelnummer: 107602 Supplement: ,
Verlag Elsevier
Verlagsort 24-28 Oval Rd, London Nw1 7dx, England
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Epidemiology (EPI)
Förderungen Canadian Institute of Health Research
TETF/DESS/POLY/OMUMA/IBR/2023
TETF/ES/POLY/IMO STATE/TSAS/2019
Alborada Foundation
University of Cambridge
TETF/DASTD/UNIV/ OWERRI/TSAS
Tetfund